AQST
Aquestive·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
FDA Approved
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AQST
Aquestive Therapeutics, Inc.
A company that developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies
30 Technology Drive, Warren, NJ 07059
--
Aquestive Therapeutics, Inc., was incorporated in Delaware in January 2004. Aquestive is a pharmaceutical company that advances medicines and brings meaningful improvements to patients' lives through innovative science and delivery technologies. The company is developing pharmaceutical products that deliver complex molecules by replacing the delivery of invasive and inconvenient standard of care therapies. Aquestive also works with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies such as PharmFilm, and has proven drug development and commercialization capabilities. The company has also developed a pipeline of products focused on the treatment of central nervous system diseases.
Earnings Call
Q1/2025
Estimate EPS-0.16
Actual EPS-0.24
Estimate Revenue12.23M
Actual Revenue8.70M
Aquestive's Q1 2025: Key Contradictions on Anaphylm's Launch Readiness, Distribution, and Market Strategy
May 20,2025 12:56
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.17
Actual EPS-0.14
Estimate Revenue11.32M
Actual Revenue10.00M
Aquestive's Q2 2025 Earnings Call: Navigating Contradictions in FDA Approval, Launch Readiness, and Market Strategy
Aug 12,2025 10:24
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AQST has released its 2025 Q3 earnings. EPS was reported at -0.14, versus the expected -0.11, missing expectations. The chart below visualizes how AQST has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AQST has released its 2025 Q3 earnings report, with revenue of 12.81M, reflecting a YoY change of -5.43%, and net profit of -15.45M, showing a YoY change of -34.21%. The Sankey diagram below clearly presents AQST's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
